两例IV期胃癌对S-1或优福定化疗有反应
[Two cases of stage IV gastric cancer responding to chemotherapy with S-1 or UFT].
作者信息
Nakamura Yukio, Yumiba Takeyoshi, Yamasaki Yoshio, Momiyama Takuya, Ito Akira, Akamaru Yusuke, Sugimoto Youko, Tamaoka Noriko, Beppu Naohito, Watanabe Yusuke, Ohno Kiyoshi, Kasugai Tsutomu
机构信息
Department of Surgery, Osaka Kosei-Nenkin Hospital.
出版信息
Gan To Kagaku Ryoho. 2007 Sep;34(9):1463-6.
We report patients with advanced Stage IV gastric cancer responding to chemotherapy with S-1 or UFT. Case 1: The patient was a 59-year-old man with Stage IV gastric cancer because of CY 1. After surgery, chemotherapy with S-1 (100 mg/body/day) was performed for one year and 11 months. At present, 5 years and 5 months after surgery, this patient shows no signs of tumor recurrence. Case 2: The patient was a 68-year-old woman with Stage IV gastric cancer because of P 1. She was treated with 200 mg/day of UFT for one year and 9 months. At present, 5 years after surgery, she shows no signs of tumor recurrence. We considered that the longterm survival of such patients is attributable to chemotherapy with S-1 or UFT. The OPRT activity of the two cases was high, so chemotherapy with S-1 or UFT was thought to be effective for them.
我们报告了晚期IV期胃癌患者对S-1或优福定化疗有反应的病例。病例1：该患者为一名59岁男性，因CY 1患有IV期胃癌。手术后，给予S-1（100mg/体/天）化疗1年11个月。目前，术后5年5个月，该患者无肿瘤复发迹象。病例2：该患者为一名68岁女性，因P 1患有IV期胃癌。她接受了200mg/天的优福定治疗1年9个月。目前，术后5年，她无肿瘤复发迹象。我们认为这些患者的长期生存归因于S-1或优福定化疗。这两个病例的OPRT活性较高，因此认为S-1或优福定化疗对他们有效。
Zotero 插件